Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: A toxicity with therapeutic implications

Journal of Clinical Oncology

Volumn 22, Issue 4, 2004, Pages 610-616

  Su, Y B ^a   Sohn, Sejean ^a   Krown, Susan E ^a   Livingston, Philip O ^a   Wolchok, Jedd D ^a   Quinn, Carolyn ^a   Williams, Linda ^a   Foster, Theresa ^a   Sepkowitz, Kent A ^a   Chapman, Paul B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; TEMOZOLOMIDE; THALIDOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; HUMAN; INFECTION; LOW DRUG DOSE; LUNG ASPERGILLOSIS; LYMPHOCYTE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MELANOMA; NEUTROPENIA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; T LYMPHOCYTE; THROMBOCYTOPENIA; ADULT; AGED; CD4+ T LYMPHOCYTE; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OPPORTUNISTIC INFECTION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CD4-POSITIVE T-LYMPHOCYTES; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOPENIA; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; OPPORTUNISTIC INFECTIONS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 1442283179     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.07.060     Document Type: Article

References (17)

1. Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166, 2000
2. Brock CS, Newlands ES, Wedge SR, et al: Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58:4363-4367, 1998
3. Biggar RJ, Rabkin CS: The epidemiology of AIDS-related neoplasms. Hematol Oncol Clin North Am 10:997-1010, 1996
4. Margolin K, Atkins B, Thompson A, et al: Temozolomide and whole brain irradiation in melanoma metastatic to the brain: A phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 128:214-218, 2002
5. Hwu WJ, Krown SE, Panageas KS, et al: Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial. J Clin Oncol 20:2610-2615, 2002
6. Khan RB, Raizer JJ, Malkin MG, et al: A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-oncol 4:39-43, 2002
7. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375-1382, 2002
8. + T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 89:3700-3707, 1997
9. + T-lymphocytopenia in long-term survivors following intensive chemotherapy in childhood cancers. Med Pediatr Oncol 30:40-45, 1998
10. Frank DA, Mahajan S, Ritz J: Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 5:444-447, 1999
11. + regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18-32, 2001
12. +) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823-832, 2001
13. + T cells restrict memory CD8+ T cell responses. J Exp Med 196:1585-1592, 2002
14. Sepkowitz KA, Brown AE, Telzak EE, et al: Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 267:832-837, 1992
15. Alvino E, Pepponi R, Pagani E, et al: O(6)-benzylguanine enhances the in vitro immunotoxic activity of temozolomide on natural or antigen-dependent immunity. J Pharmacol Exp Ther 291:1292-1300, 1999
16. Wick W, Wick A, Schulz JB, et al: Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 62:1915-1919, 2002
17. Newlands ES, Blackledge GR, Slack JA, et al: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65:287-291, 1992